H.C. Wainwright raised the firm’s price target on Sangamo (SGMO) to $10 from $5 and keeps a Buy rating on the shares. The firm says the accelerated clinical development plan in Fabry disease may support an application filing in the first half of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMO: